JP2015506960A5 - - Google Patents

Download PDF

Info

Publication number
JP2015506960A5
JP2015506960A5 JP2014555666A JP2014555666A JP2015506960A5 JP 2015506960 A5 JP2015506960 A5 JP 2015506960A5 JP 2014555666 A JP2014555666 A JP 2014555666A JP 2014555666 A JP2014555666 A JP 2014555666A JP 2015506960 A5 JP2015506960 A5 JP 2015506960A5
Authority
JP
Japan
Prior art keywords
pro
alanine
isoleucine
methionine
valine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014555666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506960A (ja
JP6225121B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/023808 external-priority patent/WO2013116312A1/en
Publication of JP2015506960A publication Critical patent/JP2015506960A/ja
Publication of JP2015506960A5 publication Critical patent/JP2015506960A5/ja
Application granted granted Critical
Publication of JP6225121B2 publication Critical patent/JP6225121B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014555666A 2012-01-31 2013-01-30 β−アレスチンエフェクターおよび組成物ならびにそれらの使用方法 Expired - Fee Related JP6225121B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592887P 2012-01-31 2012-01-31
US61/592,887 2012-01-31
PCT/US2013/023808 WO2013116312A1 (en) 2012-01-31 2013-01-30 ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Publications (3)

Publication Number Publication Date
JP2015506960A JP2015506960A (ja) 2015-03-05
JP2015506960A5 true JP2015506960A5 (cg-RX-API-DMAC7.html) 2016-03-10
JP6225121B2 JP6225121B2 (ja) 2017-11-01

Family

ID=48870731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555666A Expired - Fee Related JP6225121B2 (ja) 2012-01-31 2013-01-30 β−アレスチンエフェクターおよび組成物ならびにそれらの使用方法

Country Status (14)

Country Link
US (2) US8946142B2 (cg-RX-API-DMAC7.html)
EP (1) EP2809337A4 (cg-RX-API-DMAC7.html)
JP (1) JP6225121B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140132340A (cg-RX-API-DMAC7.html)
CN (1) CN104168907A (cg-RX-API-DMAC7.html)
AU (1) AU2013215269A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014018709A8 (cg-RX-API-DMAC7.html)
CA (1) CA2862933A1 (cg-RX-API-DMAC7.html)
EA (1) EA201491455A1 (cg-RX-API-DMAC7.html)
HK (1) HK1203379A1 (cg-RX-API-DMAC7.html)
IL (1) IL233826A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014009233A (cg-RX-API-DMAC7.html)
NZ (1) NZ627995A (cg-RX-API-DMAC7.html)
WO (1) WO2013116312A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116312A1 (en) * 2012-01-31 2013-08-08 Trevena, Inc. ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
EP3208861A1 (en) 2016-02-19 2017-08-23 Novaled GmbH Electron transport layer comprising a matrix compound mixture for an organic light-emitting diode (oled)
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925345A (en) * 1974-05-10 1975-12-09 Francis Merlin Bumpus (sar' 1',thr' 8'+9 angiotensin ii as an angiotensin antagonist
US3932624A (en) 1974-06-17 1976-01-13 Morton-Norwich Products, Inc. Method for prolonging the inhibitory effect of saralasin on angiotensin II
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4547489A (en) 1984-06-11 1985-10-15 Ortho Pharmaceutical Corporation Conformationally restricted thymopentin-like compounds
US5182264A (en) 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
DE68903907T2 (de) * 1988-09-05 1993-06-09 Sankyo Co Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
GB8822483D0 (en) 1988-09-24 1988-10-26 Medical Res Council Developments relating to mas oncogene
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
EP0608212A1 (en) 1990-08-27 1994-08-03 Peptide Technology Ltd Method of treating viral infection
EP0498361A3 (en) 1991-02-06 1992-09-02 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
PT730465E (pt) 1993-09-24 2002-06-28 Univ Southern California Utilizacao de angiotensina iii e de analogos desta em cicatrizacao de tecidos
US5958884A (en) 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
ATE268782T1 (de) 1997-12-12 2004-06-15 Univ Southern California Zusammensetzungen zur wundheilung
US20040214836A1 (en) 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20050202029A1 (en) 2003-10-03 2005-09-15 The Board Of Trustees Of The Leland Stanford Junior University Family of cystatin-related chemoattractant proteins
US20070286863A1 (en) 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
WO2008130217A1 (en) 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
GB0705488D0 (en) 2007-03-22 2007-05-02 Isis Innovation Treatment of inflammation and/or endotoxic shock
US8038992B2 (en) 2008-05-10 2011-10-18 The Board Of Trustees Of The Leland Stanford Junior University Target for regulating multiple sclerosis
US20100092974A1 (en) 2008-08-15 2010-04-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for modulators of ccrl2
NZ594302A (en) * 2008-12-29 2013-07-26 Trevena Inc Beta-arrestin effectors and compositions and methods of use thereof
US8293925B2 (en) 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
CA2802952A1 (en) * 2010-06-24 2011-12-29 Arisaph Pharmaceuticals, Inc. Niacin mimetics, and methods of use thereof
WO2013116312A1 (en) * 2012-01-31 2013-08-08 Trevena, Inc. ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Similar Documents

Publication Publication Date Title
IL262805B2 (en) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
PE20190355A1 (es) Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo
IL276294B2 (en) Human CD30 ligand antigen-binding proteins
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
AR105485A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CA2489227A1 (en) Hla-a24-restricted cancer antigen peptides
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
JP2014510518A5 (cg-RX-API-DMAC7.html)
JP2006525288A5 (cg-RX-API-DMAC7.html)
WO2014080376A3 (en) Pro-pigmenting peptides
IL276170B2 (en) Lipid-modified relaxin B peptide chains and their medical use
RU2016140627A (ru) Бета-лактамазы с улучшенными свойствами для лечения
JP2019533722A5 (cg-RX-API-DMAC7.html)
JP2017534675A5 (cg-RX-API-DMAC7.html)
NZ579566A (en) Modified fgf-21 polypeptides and their uses
RU2013131089A (ru) Пептиды тем8 и содержащие их вакцины
EP4567043A3 (en) Compounds for inducing tissue regeneration and uses thereof
NZ736652A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
JP2015504052A5 (cg-RX-API-DMAC7.html)
FI3737399T3 (fi) ATF5-peptidivariantit ja niiden käytöt
CA3010982A1 (en) Alpha chain of the high-affinity ige receptor (fceria)
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
JP2013541528A5 (cg-RX-API-DMAC7.html)
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии